Literature DB >> 21323695

Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.

Q Li1, H Yu, Y Zhang, B Wang, W Jiang, Z Da, Q Xian, Y Wang, X Liu, B Zhu.   

Abstract

Subunit vaccines have the potential advantage to boost Mycobacterium bovis Bacillus Calmette-Guérin (BCG)-primed immunity in adults. However, most candidates are antigens highly expressed in replicating bacilli but not in dormant or persisting bacilli, which exist during Mycobacterium tuberculosis infection. We constructed M. tuberculosis fusion protein Ag85B-Mpt64(190-198) -HspX (AMH) and Ag85B-Mpt64(190-198) -Mtb8.4 (AMM), which consist of Ag85B, the 190-198 peptide of Mpt64, HspX (Rv2031c) and Mtb8.4 (Rv1174c), respectively. AMH and/or AMM were mixed with adjuvants composed of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA-BCG PSN) to construct subunit vaccines. Mice were immunized thrice with Ag85B, AMH and AMM vaccines and the immunogenicity of the fusion protein vaccines was determined. Then, mice were primed with BCG and boosted twice with Ag85B, AMH, AMM and AMM + AMH vaccines, respectively, followed by challenging with M. tuberculosis virulent strain H37Rv, and the immune responses and protective effects were measured. It was found that mice immunized with AMH vaccine generated high levels of antigen-specific cell-mediated responses. Compared with the group injected only with BCG, the mice boosted with AMM, AMH and AMM + AMH produced higher levels of Ag85B-specific IgG1 and IgG2a and IFN-γ-secreting T cells upon Ag85B and Mycobacterium tuberculosis purified protein derivative (PPD) stimulation. It is interesting that only mice boosted with AMM + AMH had significantly lower bacterial count in the lungs than those receiving BCG, whereas mice boosted with AMH or AMM did not. The results suggest that AMH consisting of HspX, the antigen highly expressed in dormant bacilli, could be combined with antigens from replicating bacilli to enhance BCG primed immunity so as to provide better protection against both growing and non-growing bacteria that occur during the infection process.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323695     DOI: 10.1111/j.1365-3083.2011.02531.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  15 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

2.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

3.  HspX vaccination and role in virulence in the guinea pig model of tuberculosis.

Authors:  Agatha E Wieczorek; Jolynn L Troudt; Phillip Knabenbauer; Jennifer Taylor; Rebecca L Pavlicek; Russell Karls; Anne Hess; Rebecca M Davidson; Michael Strong; Helle Bielefeldt-Ohmann; Angelo A Izzo; Karen M Dobos
Journal:  Pathog Dis       Date:  2014-02-24       Impact factor: 3.166

Review 4.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

5.  Optimisation of human VH domain antibodies specific to Mycobacterium tuberculosis heat shock protein (HSP16.3).

Authors:  Jia Xin Soong; Soo Khim Chan; Theam Soon Lim; Yee Siew Choong
Journal:  J Comput Aided Mol Des       Date:  2019-01-28       Impact factor: 3.686

6.  Effects of the polysaccharide nucleic acid fraction of bacillus Calmette-Guérin on the production of interleukin-2 and interleukin-10 in the peripheral blood lymphocytes of patients with chronic idiopathic urticaria.

Authors:  Na Li; Na Cao; Yan-Dong Niu; Xiu-Hui Bai; Jie Lu; Yu Sun; Min Yu; Li-Xin Sun; Xin-Suo Duan
Journal:  Biomed Rep       Date:  2013-07-04

Review 7.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

8.  Multi-Functional MPT Protein as a Therapeutic Agent against Mycobacterium tuberculosis.

Authors:  Jae-Sung Kim; Euni Cho; Seok-Jun Mun; Sojin Kim; Sun-Young Kim; Dong-Gyu Kim; Wooic Son; Hye-In Jeon; Hyo-Keun Kim; Young-Jin Jeong; Sein Jang; Hyun-Sung Kim; Chul-Su Yang
Journal:  Biomedicines       Date:  2021-05-13

9.  Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection.

Authors:  Eduardo Martins de Sousa; Adeliane Castro da Costa; Monalisa Martins Trentini; João Alves de Araújo Filho; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

10.  Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery.

Authors:  Ilaria Pepponi; Elena Stylianou; Craig van Dolleweerd; Gil Reynolds Diogo; Matthew J Paul; Pascal M W Drake; Julian K-C Ma; Rajko Reljic
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.